Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Range Financial Group LLC

Range Financial Group LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 22.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,164 shares of the biopharmaceutical company’s stock after selling 10,106 shares during the period. Pfizer comprises about 1.3% of Range Financial Group LLC’s holdings, making the stock its 9th biggest position. Range Financial Group LLC’s holdings in Pfizer were worth $1,844,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter valued at $29,000. Rinkey Investments acquired a new stake in shares of Pfizer in the 4th quarter valued at about $32,000. Stuart Chaussee & Associates Inc. raised its stake in shares of Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 325 shares in the last quarter. Advanced Research Investment Solutions LLC raised its stake in shares of Pfizer by 339.3% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 509 shares in the last quarter. Finally, Bivin & Associates Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $37,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.2 %

Shares of PFE opened at $46.03 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The firm has a market cap of $258.34 billion, a P/E ratio of 9.01, a price-to-earnings-growth ratio of 0.56 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $40.94 and a fifty-two week high of $61.71. The business has a 50-day moving average of $48.99 and a 200 day moving average of $50.45.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the previous year, the company posted $1.07 EPS. Pfizer’s quarterly revenue was up 46.8% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 6.54 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s payout ratio is currently 31.31%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. Berenberg Bank set a $44.00 target price on shares of Pfizer in a research report on Wednesday, September 14th. UBS Group set a $59.00 price target on shares of Pfizer in a research report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 price objective on shares of Pfizer in a research note on Thursday, September 1st. Barclays set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Finally, Morgan Stanley lowered their target price on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.